enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 38.7% in September

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 216,700 shares, a growth of 38.7% from the August 31st total of 156,200 shares. Based on an average daily volume of 123,800 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.3% of the shares of the company are sold short.

enGene Stock Performance

ENGN traded up $0.55 on Friday, hitting $6.05. 432,716 shares of the stock traded hands, compared to its average volume of 99,694. The business has a fifty day moving average price of $7.00 and a two-hundred day moving average price of $10.78. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $267.20 million, a PE ratio of -3.52 and a beta of -0.68. enGene has a 52 week low of $4.42 and a 52 week high of $43.00.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, research analysts predict that enGene will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On enGene

Several institutional investors and hedge funds have recently bought and sold shares of the business. Altitude Crest Partners Inc. acquired a new stake in shares of enGene during the 1st quarter valued at about $2,039,000. SR One Capital Management LP bought a new stake in shares of enGene in the 2nd quarter valued at approximately $4,715,000. Omega Fund Management LLC bought a new stake in shares of enGene in the 4th quarter valued at approximately $10,441,000. Logos Global Management LP raised its holdings in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new position in shares of enGene during the 1st quarter worth approximately $17,095,000. Institutional investors own 64.16% of the company’s stock.

Wall Street Analysts Forecast Growth

ENGN has been the topic of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $30.00 target price on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, enGene presently has an average rating of “Buy” and a consensus price target of $33.67.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.